INDP Company Profile and Key Details

Indaptus Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $8.81. This means the shares are trading below this model’s fair value.

Indaptus Therapeutics, Inc. (NASDAQ:INDP) closed at $1.85 USD, gaining $0.63 (51.64%) from the previous close of $1.22. The stock is currently mid-range between its 52-week high and low $0.92 and $8.57. With a market capitalization of about $209.50 million, Indaptus Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.17). Key stats such as the average daily volume over the past year has been around 478.70 thousand shares, trading with heavier-than-usual volume. Headquartered in New York City, NY, Indaptus Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Junyi Dai, the company employs approximately 5 people and listed since August 04, 2015. Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections.

Short-term trend indicators are bullishly aligned (SMA20 9.28%, SMA50 -11.74%, SMA200 -61.99%). The stock’s 14-day RSI is 49.38 (neutral), while the ATR of 0.22 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -95.67% below its high and over 35.72% above its low. Average 10-day trading volume of 1.54 million shares is significantly above the 3-month average of 618.31 thousand, indicating heightened recent market interest.

Indaptus Therapeutics, Inc. generated EPS of -$31.51 over the past year. Five-year average earnings growth is 57.27%. Wall Street analysts project EPS growth of 53.89% annually over the next five years. The latest quarter delivered EPS of -$0.02. The next quarter is forecast at -$4.36. Next year's EPS is expected at $8.95. Indaptus Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended August 13, 2026, missed forecasts by -98.73%. The prior quarter beat by -87.7%. Over the last six quarters, Apple has recorded several small beats. These include -21.95% in May 14, 2025.

Indaptus Therapeutics, Inc. has 133.24 million shares outstanding. The public float is 3.24 million shares, elevated short interest at 0.20% of float. This equals 259.72 thousand shares. The short ratio is 1.52 days. Institutional investors hold 3.35% of the float. Insiders own 97.01%. Newman Michael James holds 1.37 million shares, Anderson Glen R. has 1.19 million shares and Meckler Jeffrey A has 75.37 thousand shares. Over the past six months, insider transactions show net selling. They sold 700.00 thousand shares across 1 transactions.

Indaptus Therapeutics, Inc. trades at a P/E ratio of -0.26, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 18.79 reflecting a rich premium to book value. The P/FCF stands at -13.72, also below market averages. Compared to sector medians, Indaptus Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Indaptus Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -20.0%, with price expected at $1.48 by September 22, 2026, within a range of $1.02 to $1.88 3-Month Outlook: Projected fall of -40.54%, reaching $1.10 by December 07, 2026, with a range of $0.77 to $1.37. 1-Year Outlook: Projected loss of -59.46%, with price at $0.75 by September 08, 2027, within a range of $0.00 to $0.00.

Indaptus Therapeutics, Inc. (NASDAQ:INDP) shares are flat -0.69% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Indaptus Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.26. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.60, suggesting 581.08% upside. Our AI forecast model points to short-term weakness (-20.0% over two weeks), a medium-term fall (-40.54% over three months), and a longer-term loss (-59.46% over one year), with expected trading ranges indicating moderate volatility.